Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists
- 22 October 2009
- journal article
- research article
- Published by Informa UK Limited in Journal of Immunotoxicology
- Vol. 6 (4), 257-265
- https://doi.org/10.3109/15476910903286733
Abstract
Toll-like receptor (TLR)-mediated signaling is proposed as an immunotherapeutic target against tumorigenesis. Natural killer (NK) cells play a critical role in host defense against tumors. Specifically, formation of tumor metastasis in various organs can be suppressed by the local activity of NK cells. In this study, we present a novel TLR7 agonist (termed SC-1) that induces pro-inflammatory cytokines in human blood cells, activates NK cell function, and is highly efficient in preventing lung metastases in a pulmonary metastatic Renca model. Furthermore, a second compound (termed SC-2), acting as dual-specific TLR7 and TLR8 agonist, was evaluated with respect to its immunostimulatory and NK cell–activating capacities. The release of pro-inflammatory cytokines was shown to be even more pronounced with this compound. Additional experiments showed a significant up-regulation of activation marker CD69 on NK cells and increased cytolytic activity of peripheral blood cells compared to the effect of a monospecific TLR7 agonist SC-1. Normally, TLR7 and TLR8 are expressed on different immune cell subpopulations. TLR7 expression on antigen-presenting cells is detected in plasmacytoid dendritic cells, CD34+-derived dendritic cells, and B-cells, whereas TLR8 is mainly expressed on cells of the myeloid lineage, such as monocytes, macrophages, and myeloid dendritic cells. Therefore, a compound that activates both TLR7 and TLR8 would result in a highly efficient immune system activation and may give rise to an enhanced anti-tumor activity in vivo compared to that elicited by a monospecific TLR7 agonist.Keywords
This publication has 62 references indexed in Scilit:
- Development of TLR9 agonists for cancer therapyJCI Insight, 2007
- Immune surveillance of tumorsJCI Insight, 2007
- Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin LymphomaJournal of Immunotherapy, 2006
- Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletionBlood, 2005
- TLR11 Activation of Dendritic Cells by a Protozoan Profilin-Like ProteinScience, 2005
- Imiquimod 5% cream for the treatment of actinic keratosis: Results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histologyJournal of the American Academy of Dermatology, 2004
- Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studiesJournal of the American Academy of Dermatology, 2004
- Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activitiesEuropean Journal of Immunology, 2003
- The Toll‐like receptor 7 (TLR7)‐specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamilyEuropean Journal of Immunology, 2003
- Endotoxin-tolerant Mice Have Mutations in Toll-like Receptor 4 (Tlr4)The Journal of Experimental Medicine, 1999